AMGEVITA 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0033 
B.II.e.6.a - Change in any part of the (primary) 
09/01/2023 
packaging material not in contact with the finished 
product formulation - Change that affects the product 
information 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
II/0031 
B.II.b.2.c.3 - Change to importer, batch release 
10/11/2022 
n/a 
arrangements and quality control testing of the FP - 
Including batch control/testing for a biol/immunol 
product and any of the test methods is a 
biol/immunol/immunochemical method 
IA/0030 
B.II.e.6.b - Change in any part of the (primary) 
07/03/2022 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect the 
product information 
R/0029 
Renewal of the marketing authorisation. 
14/10/2021 
09/12/2021 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
AMGEVITA in the approved indication remains favourable 
and therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
IB/0027/G 
This was an application for a group of variations. 
21/07/2021 
12/08/2021 
SmPC, 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
WS/2026 
This was an application for a variation following a 
08/07/2021 
n/a 
worksharing procedure according to Article 20 of 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commission Regulation (EC) No 1234/2008. 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test method 
at the site is a biol/immunol method 
IAIN/0028 
B.II.b.1.a - Replacement or addition of a 
21/06/2021 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0025 
B.I.b.2.a - Change in test procedure for AS or starting 
16/04/2021 
n/a 
material/reagent/intermediate - Minor changes to an 
approved test procedure 
IB/0024 
C.I.11.z - Introduction of, or change(s) to, the 
21/01/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0023 
B.I.b.2.d - Change in test procedure for AS or starting 
14/01/2021 
n/a 
material/reagent/intermediate - Substantial change to 
or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
PSUSA/10783
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC Recommendation - maintenance 
/201912 
adalimumab 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/02/2020 
02/06/2020 
SmPC, Annex II 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
and PL 
IA/0020 
B.II.d.2.a - Change in test procedure for the finished 
06/11/2019 
n/a 
product - Minor changes to an approved test 
procedure 
II/0019/G 
This was an application for a group of variations. 
26/09/2019 
02/06/2020 
Annex II 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting material 
[-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test method 
at the site is a biol/immunol method 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/10589
Periodic Safety Update EU Single assessment - 
11/07/2019 
n/a 
PRAC Recommendation - maintenance 
/201812 
adalimumab (biosimilars) 
II/0017 
B.II.e.4.b - Change in shape or dimensions of the 
04/07/2019 
n/a 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
container or closure (immediate packaging) - The 
change in shape or dimensions concerns a 
fundamental part, which may have a significant 
impact on the delivery, use, safety or stability of the FP 
IAIN/0018 
B.II.e.6.a - Change in any part of the (primary) 
14/06/2019 
02/06/2020 
SmPC, 
packaging material not in contact with the finished 
product formulation - Change that affects the product 
information 
Labelling and 
PL 
IB/0015/G 
This was an application for a group of variations. 
14/03/2019 
28/03/2019 
SmPC, Annex II 
and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
IB/0014 
B.I.a.1.k - Change in the manufacturer of AS or of a 
04/01/2019 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IB/0012/G 
This was an application for a group of variations. 
31/10/2018 
28/11/2018 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0013 
B.II.g.5.c - Implementation of changes foreseen in an 
03/09/2018 
n/a 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0010 
C.I.11.z - Introduction of, or change(s) to, the 
08/08/2018 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IAIN/0011 
B.II.e.5.a.1 - Change in pack size of the finished 
20/07/2018 
29/10/2018 
SmPC and 
product - Change in the number of units (e.g. tablets, 
Labelling 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
IAIN/0009 
B.II.e.5.a.1 - Change in pack size of the finished 
20/07/2018 
29/10/2018 
SmPC and 
product - Change in the number of units (e.g. tablets, 
Labelling 
ampoules, etc.) in a pack - Change within the range of 
the currently approved pack sizes 
PSUSA/10589
Periodic Safety Update EU Single assessment - 
12/07/2018 
n/a 
PRAC Recommendation - maintenance 
/201712 
adalimumab (biosimilars) 
IG/0946 
B.II.b.2.c.1 - Change to importer, batch release 
04/06/2018 
29/10/2018 
PL 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
WS/1373/G 
This was an application for a group of variations 
26/04/2018 
29/10/2018 
SmPC and PL 
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008. 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
WS/1358 
This was an application for a variation following a 
12/04/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.g.5.c - Implementation of changes foreseen in an 
approved change management protocol - For a 
biological/immunological medicinal product 
WS/1313/G 
This was an application for a group of variations 
14/12/2017 
29/10/2018 
SmPC and PL 
following a worksharing procedure according to Article 
20 of Commission Regulation (EC) No 1234/2008. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by the 
MAH 
IG/0853 
B.II.b.2.c.1 - Change to importer, batch release 
10/11/2017 
29/10/2018 
Annex II and PL 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - Not 
including batch control/testing 
WS/1182 
This was an application for a variation following a 
01/09/2017 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Submission of the final report from study/studies 
20130258, an open-label, single-arm extension study 
to evaluate the long-term safety and efficacy of ABP 
501 in subjects with moderate to severe rheumatoid 
arthritis, listed as a category 3 study in the RMP 
(MEA002). No changes of the PI are proposed; the 
RMP is updated accordingly (version 2.0). 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
Page 10/10 
 
 
 
 
 
 
 
